India’s pharma exports grew 6.8% in Q1 FY27: Pharmexcil
India’s pharmaceutical exports rose 6.8% to $8.1 billion in April-June FY27, with the US remaining the top market, Pharmexcil data showed.
India's pharmaceutical exports reached $8.10 billion during the first quarter of FY 2026-27, marking a 6.8% increase compared to $7.58 billion in the same period last year, despite potential US tariff concerns. The Pharmaceuticals Export Promotion Council of India (Pharmexcil) reported this data, highlighting the continued strength of India's pharmaceutical exports in global markets.
June exports grew by 7.13% to $2.81 billion, with a 6.86% increase from May's $2.63 billion. Drug formulations and biologicals led exports, contributing $5.98 billion or 73.85% of total exports, while bulk drugs and drug intermediates grew by 13.84% to $1.36 billion. Vaccine exports surged by 35.68% to $0.39 billion, making it the fastest-growing segment.
Major export destinations include NAFTA (34.28%), the US (30.89%), and other regions like Europe, Africa, and Latin America. Pharmexcil's chairman, Namit Joshi, emphasized the sector's ability to combine scale in established markets with growth across new geographies, urging continued investments in advanced manufacturing and regulatory compliance to sustain momentum.
Written by urgent.news from Hindustan Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
